- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Arecor Therapeutics - Arecor Appoints Interim Chief Financial Officer | - | RNS | ||
| 27.09. | Arecor Therapeutics - Arecor to present on Investor Meet Company | - | RNS | ||
| 26.09. | Arecor Therapeutics - Interim Results for six months ended 30 June 2024 | - | RNS | ||
| 19.09. | Arecor Therapeutics - Notice of Results | - | RNS | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Arecor Therapeutics - Arecor presents positive AT278 data at EASD | - | RNS | ||
| 03.09. | Arecor Therapeutics - Arecor announces AT278 presentation at EASD 2024 | - | RNS | ||
| 08.08. | Arecor Therapeutics - Result of General Meeting and Total Voting Rights | 2 | RNS | ||
| 23.07. | Arecor Therapeutics - Posting of Circular and General Meeting | - | RNS | ||
| 23.07. | Arecor Therapeutics - Result of WRAP Retail Offer | - | RNS | ||
| 19.07. | Arecor Therapeutics - Result of Placing and Subscription | 1 | RNS | ||
| 19.07. | Arecor Therapeutics - WRAP Retail Offer to raise up to £1 million | - | RNS | ||
| 19.07. | Arecor Therapeutics - Proposed Placing and Subscription | 1 | RNS | ||
| 28.06. | Arecor Therapeutics - Result of AGM | - | RNS | ||
| 10.06. | AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs | 1 | Alliance News | ||
| 10.06. | Arecor Therapeutics shares dive as says needs funding in third quarter | 2 | Alliance News | ||
| 10.06. | Arecor Therapeutics shares tank on funding update | 1 | Sharecast | ||
| 10.06. | Arecor Therapeutics - Trading and Funding Update | 1 | RNS | ||
| 31.05. | Arecor Therapeutics - Posting of 2023 Annual Report and Notice of AGM | 1 | RNS | ||
| 20.05. | Arecor Therapeutics plc: At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes | 104 | GlobeNewswire (Europe) | Arecor Therapeutics plc("Arecor" or "the Company") AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2... ► Artikel lesen | |
| 09.05. | Arecor Therapeutics plc: Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery | 1.034 | GlobeNewswire (Europe) | Arecor Therapeutics plc("Arecor" or the "Company") ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor's... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,850 | -0,56 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
| QIAGEN | 40,250 | +3,63 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
ARECOR THERAPEUTICS PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,885 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.
